A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation(HSCT) Consolidation. - niet van toepassing.

Daiichi Sankyo, Inc.0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: Daiichi Sankyo, Inc.
入组人数: 20

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•1. Provision of written informed consent approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) with privacy language in accordance with national regulations (e.g., HIPAA authorization for US sites) prior to any study-related procedures, including withdrawal of prohibited medications if applicable. ;2. Age >=18 years at the time of informed consent. ;3. Morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS), as defined by World Health Organization criteria, as determined by pathology review at the study site.;4.In first relapse (with duration of remission of 6 months or less) or refractory after prior therapy, with or without HSCT. Induction therapy must have included at least 1 cycle of an anthracycline/mitoxantrone containing induction block at a standard dose.
•Refractory is defined as:
•After 1 cycle, a reduction in bone marrow blasts of less than 50% and failure to achieve a CR, CRp or CRi.
•After 2 cycles, lack of achievement of CR, CRp, or CRi
•First relapse (with duration of remission of 6 months or less) is defined as:
•Achievement of CR, CRi, or CRp, as defined by 2003 International Working Group criteria after initial AML therapy with or without consolidation or maintenance, and with or without HSCT
•Duration of CR, CRi or CRp is measured from the date of the bone marrow assessment which confirmed response or the date of allogeneic transplantation to the date of the bone marrow assessment that identified relapse or the appearance of peripheral blasts.;5. Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood (allelic ratio as determined by a central laboratory with a cutoff of >3% FLT3ITD/total FLT3).;6. Eligibility for pre-selected salvage chemotherapy, according to the Investigator*s assessment. ;7. ECOG performance score 0-2.;8.Discontinuation of prior AML treatment before the start of study treatment (except hydroxyurea or other treatment to control leukocytosis) for at least 2 weeks for cytotoxic agents, or for at least 5 half-lives for non cytotoxic agents.
•9. Serum creatinine <=1.5×upper limit of normal (ULN), or glomerular filtration rate >25 mL/min, as calculated with the Cockcroft-Gault formula.;10. Serum potassium, magnesium, and calcium (serum calcium corrected for hypoalbuminemia) within institutional normal limits. Subjects with electrolytes outside the normal range will be eligible if these values are corrected upon retesting following any necessary supplementation. ;11. Total serum bilirubin <=1.5×ULN.;12. Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) <=2.5×ULN.

排除标准

•1. Acute promyelocytic leukemia (AML subtype M3).
•2. AML secondary to prior chemotherapy for other neoplasms, except AML secondary to prior MDS.
•3. History of another malignancy, unless the candidate has been disease-free for at least 5 years.
•Candidates with treated non-melanoma skin cancer, carcinoma in situ, or cervical intraepithelial neoplasia are eligible regardless of the time spent disease-free, if they have completed definitive treatment.
•Candidates with organ-confined prostate cancer, with no evidence of recurrent or progressive disease, are eligible if hormonal therapy has been begun, or if thetumor has been surgically removed or treated with definitive radiotherapy.
•4. Persistent, clinically significant > Grade 1 non-hematologic toxicity from prior AML therapy.
•5. Clinically significant GVHD or GVHD requiring initiation of treatment or treatment escalation within 21 days, and/or > Grade 1 persistent or clinically significant nonhematologic toxicity related to HSCT.
•6. History of, or current, central nervous system involvement with AML.
•7. Clinically significant coagulation abnormality, such as disseminated intravascular coagulation.
•8. Prior treatment with quizartinib or participated in a prior quizartinib study.
•9. Prior treatment with a FLT3 targeted therapy including sorafenib or investigational FLT3 inhibitors.
•10. Major surgery within 4 weeks prior to screening.
•11. Radiation therapy within 4 weeks prior to screening.
•12. Uncontrolled or significant cardiovascular disease, including:
•QT interval corrected using Fridericia's formula (QTcF) interval >450 msec (average of triplicate determinations).
•Subject has bradycardia of less than 50 BPM (as determined by central read) unless the subject has a pacemaker.
•Diagnosed or suspected long QT syndrome, or known family history of long QT syndrome.
•History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or torsade de pointes.
•History of second or third degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers, and have no history of fainting or clinically relevant arrhythmia with pacemakers.
•Myocardial infarction within 6 months prior to screening.
•Uncontrolled angina pectoris within 6 months prior to screening.
•New York Heart Association (NYHA) Class 3 or 4 congestive heart failure.
•Left ventricular ejection fraction (LVEF) <=45 % or institutional lower limit of normal.
•Uncontrolled hypertension.
•Complete left or right bundle branch block.
•13. Active infection not well controlled by antibacterial, antifungal, and/or antiviral
•14. Known infection with human immunodeficiency virus, or active hepatitis B or C, or other active clinically relevant liver disease.
•15. Unwillingness to receive infusion of blood products according to the protocol.;16.In a man whose sexual partner is a woman of childbearing potential, unwillingness or inability of the man or woman to use an highly effective contraceptive method for the entire study treatment period and for at least 3 months after study treatment completion.
•Male subjects must not freeze or donate sperm starting at Screening and throughout the study period and 105 days after the final study drug administration.
•17.In a woman of childbearing potential unwillingness or inability

研究者

发起方

Daiichi Sankyo, Inc.

相似试验

进行中（未招募）

1 期

A Phase 3 Open-Label clinical trial of the drug Quizartinib (AC220) compared to recovery treatment in patients with Acute Myeloid Leukemia (AML), a cancer of the blood.Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)MedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864

EUCTR2013-004890-28-PLDaiichi Sankyo Inc367

进行中（未招募）

1 期

A Phase 3 Open-Label clinical trial of the drug Quizartinib (AC220) compared to recovery treatment in patients with Acute Myeloid Leukemia (AML), a cancer of the blood.Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)MedDRA version: 19.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864

EUCTR2013-004890-28-CZDaiichi Sankyo Inc.367

进行中（未招募）

1 期

A Phase 3 Open-Label clinical trial of the drug Quizartinib compared to recovery treatment in patients with Acute Myeloid Leukemia (AML), a cancer of the blood.Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)MedDRA version: 20.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864

EUCTR2013-004890-28-DEDaiichi Sankyo Inc.367

进行中（未招募）

1 期

EUCTR2013-004890-28-BEDaiichi Sankyo Inc367

进行中（未招募）

1 期

A Phase 3 Open-Label clinical trial of the drug Quizartinib compared to recovery treatment in patients with Acute Myeloid Leukemia (AML), a cancer of the blood.Refractory or Relapsed FLT3-ITD Positive Acute Myeloid Leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864

EUCTR2013-004890-28-NLDaiichi Sankyo Inc367